Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
The Pfizer Inc. (NYSE: PFE) news page on Stock Titan aggregates company announcements, clinical data readouts, financial updates and legal developments for one of the world’s major biopharmaceutical manufacturers. Pfizer’s news flow reflects its role in pharmaceutical preparation manufacturing, with frequent updates on prescription medicines, vaccines and late‑stage clinical programs.
Investors and observers can find detailed coverage of oncology trial results, such as Phase 3 data for BRAFTOVI (encorafenib) combinations in BRAF V600E‑mutant metastatic colorectal cancer, PADCEV (enfortumab vedotin) plus pembrolizumab in muscle‑invasive bladder cancer, and TUKYSA (tucatinib) in HER2‑positive metastatic breast cancer. These releases typically report on endpoints like objective response rate, progression‑free survival, event‑free survival and overall survival, along with safety profiles and plans for regulatory discussions.
Pfizer news also includes corporate and financial communications, such as earnings webcasts, performance reports, forward‑year revenue and adjusted EPS guidance, and dividend declarations. Recent releases describe full‑year revenue guidance ranges, expected contributions from COVID‑19 products, the impact of loss of exclusivity for certain medicines, and ongoing cost realignment efforts. Dividend announcements highlight Pfizer’s long record of consecutive quarterly cash dividends.
Another important category is business development and pipeline expansion. News items cover transactions like the acquisition of Metsera, which adds GLP‑1‑based obesity candidates, and an exclusive global collaboration and license agreement with YaoPharma for the small‑molecule GLP‑1 receptor agonist YP05002. These updates explain how Pfizer is building its cardiometabolic and obesity portfolio.
Regulatory, safety and legal topics also appear in the news stream, including multidistrict litigation related to Depo‑Provera and FDA label changes adding brain tumor warnings. By following this page, readers can monitor how scientific, financial and legal events shape Pfizer’s outlook and product portfolio over time.
Pfizer (NYSE: PFE) has received European Commission approval for an expanded indication of its RSV vaccine ABRYSVO®. The authorization now includes prevention of lower respiratory tract disease (LRTD) in adults aged 18-59, extending beyond its previous approval for those 60 and older.
ABRYSVO becomes the first and only RSV vaccine approved in the European Union for non-pregnant adults aged 18-49. The vaccine now offers the broadest RSV indication in the EU, covering both active immunization for adults 18 and older, and passive protection for infants through maternal immunization during pregnancy.
The approval is supported by the phase 3 clinical trial MONeT (NCT05842967), which evaluated the vaccine's safety, tolerability, and immunogenicity in adults 18-59 years with risk factors for RSV-associated LRTD. RSV causes approximately 158,000 adult hospital admissions annually in the EU.
Dexcom (NASDAQ: DXCM), the global leader in glucose biosensing, has appointed Jon Coleman as Chief Commercial Officer. Coleman brings over 30 years of global commercial leadership experience and will oversee Dexcom's global commercial organization, including sales, marketing, and customer experience.
Coleman previously served as an executive officer at Masimo (NASDAQ: MASI) for 15 years, where he was president of commercial teams. He managed worldwide hospital sales, OEM, alternate care sales, clinical teams, and customer service. Prior to Masimo, Coleman held leadership positions at Pfizer (NYSE: PFE) Consumer Healthcare, including vice president and general manager of Canada and the Caribbean region, with additional experience in Asia and Latin America.
Throughout his career, Coleman has demonstrated success in scaling operations, developing innovative products, entering new markets, and delivering strong growth performance.
Pfizer (NYSE: PFE) has announced a conference call with investment analysts scheduled for April 29, 2025, at 10:00 a.m. EDT. The call will provide updates on the company's First Quarter 2025 Performance Report, which will be released that morning.
Investors and the public can access the webcast through www.pfizer.com/investors. Participants can also join via phone by dialing 800-456-4352 (US/Canada) or 785-424-1086 (international) using passcode '67619'. The webcast replay and transcript will be available on Pfizer's investor website within 24 hours and remain accessible for 90 days.
Pfizer, with a 175-year legacy, continues its mission of developing innovative medicines and vaccines. The company emphasizes its commitment to quality healthcare, global wellness, and breakthrough therapies that address critical diseases.
ViiV Healthcare has announced groundbreaking results from implementation studies for their HIV prevention injectable Apretude and treatment injectable Cabenuva at CROI 2025. The studies demonstrated remarkable effectiveness with zero HIV acquisitions reported in nearly 4,000 people using Apretude for prevention.
The PILLAR study, involving 201 participants across 17 U.S. clinics, showed zero HIV cases over 12 months, with 72% persistence rate. The ImPrEP CAB Brazil study of 1,447 participants demonstrated superior PrEP coverage with Apretude (96.2%) compared to oral PrEP (64.1%).
For Cabenuva treatment, real-world data from the OPERA analysis (n=2,485) showed 95% of patients maintained viral suppression, with only 1% experiencing confirmed virologic failure. The Trio Health cohort (n=928) similarly demonstrated 95% viral suppression maintenance, with 89% of injections administered on schedule.
ViiV Healthcare announced positive results from its phase IIb EMBRACE study evaluating N6LS (VH3810109), a broadly neutralising antibody for HIV treatment. When administered every four months in combination with monthly cabotegravir long-acting (CAB LA), N6LS effectively maintained viral suppression in HIV patients stable on treatment.
Key findings at the six-month endpoint showed that 96% of participants receiving N6LS 60mg/kg intravenously and 88% receiving 3000mg subcutaneously maintained HIV-1 RNA levels below 50 copies/mL, compared to 96% in the standard-of-care group. The treatment was generally well-tolerated, though subcutaneous administration showed more frequent infusion site reactions (14%) compared to none with IV administration.
Based on these favorable results, ViiV Healthcare will advance development of a six-month IV formulation of N6LS in combination with CAB LA in an EMBRACE part two trial.
ViiV Healthcare announced positive results from two phase IIa studies of investigational HIV therapies at CROI 2025. The studies focused on VH4524184 (VH184), a third-generation integrase inhibitor, and VH4011499 (VH499), a capsid inhibitor, both showing promise as long-acting injectable treatments.
VH184 demonstrated significant antiviral activity across three doses (10mg, 50mg, 300mg) in 22 treatment-naive adults. The 300mg dose achieved the maximum viral load decline of -2.69 log10 copies/mL. All side effects were mild to moderate with no serious adverse events.
VH499 showed positive results in 23 treatment-naive adults across doses of 25mg, 100mg, and 250mg. The highest dose (250mg) achieved a -2.2 log10 copies/mL decrease in HIV-1 viral load. The treatment was well-tolerated with only mild to moderate adverse events reported.
FoRx Therapeutics has appointed Dr. Jens Würthner as Chief Medical Officer, bringing over 20 years of clinical development expertise in oncology therapeutics. Dr. Würthner's experience includes successful drug development at companies like Novartis, GlaxoSmithKline, AstraZeneca, and ADC Therapeutics, where he oversaw the development of loncastuximab teserine (Zynlonta).
The company also provided an update on FORX-428, their lead development candidate targeting solid tumors. This PARG (Poly(ADP-ribose) glycohydrolase) inhibitor is progressing toward IND submission by mid-2025. Recent developments include:
- Completion of GLP toxicological testing
- Identification of predictive biomarkers for patient selection
- Promising animal studies showing strong anti-tumor efficacy and good tolerability
Akeso announced that its partner Summit Therapeutics (NASDAQ: SMMT) has entered a clinical trial collaboration with Pfizer (NYSE: PFE) to evaluate ivonescimab, a novel PD-1/VEGF bispecific antibody, in combination with several of Pfizer's antibody drug conjugates (ADCs) across multiple solid tumor settings.
The collaboration aims to accelerate development of potentially landscape-changing combinations to improve standards of care for cancer patients with serious unmet needs. Each study will evaluate ivonescimab plus one of Pfizer's vedotin ADCs in distinct solid tumor settings to determine safety profiles and potential anti-tumor activity.
Under the agreement, Summit will provide ivonescimab while Pfizer will conduct the studies, with oversight from both companies. Both parties retain rights to their respective products. The studies are planned to begin in mid-2025, with further details to be announced later.
Pfizer (NYSE: PFE) has announced a public webcast featuring a discussion with Albert Bourla, Chairman and CEO, at the TD Cowen 45th Annual Health Care Conference on March 3, 2025, at 10:30 a.m. EST.
The webcast will be accessible through www.pfizer.com/investors, with registration details available immediately. A transcript and replay will be posted within 24 hours after the live discussion and remain accessible for at least 90 days.
The discussion may include forward-looking statements about Pfizer's operating performance, product pipeline, business strategy, COVID-19 response, and ESG priorities. These statements are subject to risks and uncertainties as detailed in Pfizer's Annual Report on Form 10-K and subsequent SEC filings.
Summit Therapeutics (NASDAQ: SMMT) has announced a clinical trial collaboration with Pfizer (NYSE: PFE) to evaluate ivonescimab, a novel PD-1/VEGF bispecific antibody, in combination with Pfizer's antibody drug conjugates (ADCs) across multiple solid tumor settings.
The collaboration aims to assess ivonescimab with several of Pfizer's vedotin-based ADCs in distinct solid tumor settings to determine safety profiles and potential anti-tumor activity. Summit will provide ivonescimab while Pfizer will conduct the studies, with both companies overseeing the trials. Both parties maintain their respective product rights.
The clinical trials are scheduled to begin in mid-2024, with further details to be announced later. The partnership focuses on developing novel mechanisms beyond current available treatments, particularly targeting non-small cell lung cancer and other solid tumors.